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HLA-DQ gene polymorphism in primary IgA nephropathy in three
European populations. MHC Class II genes may contribute to suscepti-
bility to IgA nephropathy (IgAN). We have previously identified a
restriction fragment length polymorphism (RFLP) of the DQB1 region
that associated with IgAN in British Caucasoids. However, another group,
while demonstrating a DQB1 association, was unable to confirm our
finding. MHC molecules are heterodimers consisting of an a and J3 chain,
and thus polymorphism of the DQA1 a chain may also be important to
disease pathogenesis in IgAN. Therefore, we have determined DOA1
alleles and re-examined DQB1 alleles in British Caucasoids with IgAN
using an approach that can differentiate between the common DO alleles;
we have also extended our studies to Caucasoid populations from North-
ern and Southern Europe, thereby addressing the possibility of variation in
genetic susceptibility between populations. DNA was prepared from IgAN
patients (British, N = 105; Italian, N 71; Finnish, N = 48) and healthy
controls (British, N = 111; Italian, N 63; Finnish, N = 41). DQA1 alleles
were identified by TaqI RFLP and Southern blotting; alleles that could not
be fully resolved by Taq Southern blotting were identified by PCR-RFLP.
DQB1 alleles were identified by polymerase chain reaction (PCR) based
technique (PCR-RFLP). No consistent association of DQ alleles were
found between the populations studied. In British patients a decreased
fequency of DQBI*0201 was observed (P = 0.008), in Finnish patients a
decreased frequency of DQB1*0602 was observed (P 0.01), and in
Italian patients no association between DO markers and IgAn was found.
These data demonstrate population variation in disease association, but
no strong or consistent association in the DQ region.
Much clinical and experimental evidence indicates that IgA
nephropathy (IgAN) is an immune complex mediated form of
glomerulonephritis, and several features point to an important
genetic component [1—5]. The search for susceptibility loci has
centred on the major histocompatibility complex (MHC) using
disease association in family and population studies. Associations
between IgAN and the MHC have been noted, but these have been
inconsistent both between and within different populations [6].
The first MHC associations with IgAN were reported for the
Class I antigens HLA-B35, B12, B44 and Cwl [7], but these have
not always been confirmed by other studies [8]. Class III comple-
ment factors may also be involved in disease pathogenesis [9].
MHC Class II molecules are important determinants of the
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immune response and susceptibility alleles for several autoim-
mune diseases have now been located to the Class II region. The
prime example is insulin-dependent diabetes mellitus in which
susceptibility is believed to be partly determined by amino acid
variation of both the DOes and D013 molecules affecting the
conformation of the antigen binding groove and hence antigen
presentation [10]. In Japan, DR4 has repeatedly been shown to be
increased in patients with IgAN [11—15], but the implications of
DR4 positivity on disease prognosis are unclear [13, 14]. Among
other populations DR4 has been associated with IgAN in France
[16], a finding not confirmed in three later studies [17—19]. DR1
has been associated with IgAN in Britain [20] and in the United
States [21], although other studies have not confirmed this [22—241
and no associations were found in Ireland [25].
Closer analysis of the Class II region in Japanese IgAN patients
has shown a stronger disease association with HLA-DQw4 than
DR4 [15, 26]. Similarly, two studies have documented an associ-
ation of IgAN with the DQB1 locus in British Caucasoid subjects
in the absence of a DR association [22, 23]. We examined RFLPs
of the DQB1 region and found a TaqI RFLP fragment (DQB1-T2
[sized 1.9 kb], which identifies DQB1*0302, *0303 and *0402 [27])
associated with IgAN [22]. In contrast, another group used RFLP
analysis combined with oligonucleotide hybridization and found
an association with DQB1*0301 [23]. As has been found in
insulin-dependent diabetes polymorphism of the DOes chain may
also be important in IgAN; however, in the previous study no
association existed.
To investigate these findings further we have completed a
trans-European study of DQA1 and DQB1 alleles in three distinct
populations of Caucasoid subjects from Northern, Central and
Southern Europe: Finland, Britain and Italy, respectively. We
have already studied RFLPs of TNFI3 (located telomeric of the
DR loci) and HLA-DPA1 and -DPBI (located centromeric of DQ
loci) in these three populations and found them not to be
associated with IgAN [28, 29], raising the possibility that if
susceptibility exists in the Class II region it is confined to the DQ
region. Ethnic and regional differences in disease prevalence are
present in IgAN [30], but if a locus is of primary importance in
determining susceptibility then its association should be present in
different populations. Understanding of the Class II region has
expanded markedly in recent years, and now at least 8 DQA1
alleles and 14 DQB1 alleles can be confidently analyzed, thus
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making this type of study highly discriminatory and the associa-
tions more precise.
Methods
Patients and controls
All the subjects studied were unrelated Caucasoids from Brit-
ain, Italy or Finland.
IgAN patients. British patients (N = 105) with biopsy proven
primary IgAN and with no clinical or serological evidence of
Henoch SchOnlein purpura, systemic lupus erythematosus, alco-
holic liver disease, or immunological diseases with recognized
associations with IgAN, were recruited from the Renal Units of
The Royal London, St Philip's, and St Thomas' Hospitals, London,
and the Freeman Hospital, and Royal Victoria Infirmary, Newcastle.
In addition, DNA was obtained from Italian (N = 71) and Finnish
(N = 48) patients with primary IgAN from the Renal Units at San
Carlo Hospital, Milan, Italy, and the Tampere University Hospital,
Tampere, Finland. At diagnosis, the number of patients presenting
with macroscopic hematuria or renal impairment (creatinine greater
than 125 jLmol/liter) were documented.
Normal controls. Healthy subjects with no history of renal
disease were recruited from staff at San Carlo Hospital (N = 63),
the University of Tampere (N = 41), the Royal London Hospital
Medical College (N = 48) and from school aged children in the
Oxford region (N = 63), thus making a total of 111 British
Caucasoid controls. HLA-DQ results in the Oxford children have
previously been reported by us [311.
HLA-DQ typing
DNA was extracted from whole blood samples and DQA1
alleles determined by Southern blot hybridization methods as
previously reported [22]. DNA was digested with the restriction
enzyme TaqI, the DNA electrophoresed in 0.85% agarose gel and
transferred to a nylon membrane. Membranes were hybridized
with nick translated 32P-labeled cDNA DQAI probe (2.0 kb PstI
insert, donated by J. Trowsdale, Imperial Cancer Research Fund,
London, UK). All membranes were washed down to a high
stringency (0.2 X SSC) and visualised by autoradiography using
Kodak XAR5 film in the presence of two high speed intensifying
screens for 36 hours at —70°C. Hybridization bands were sized by
comparison with an internal genomic DNA control and Hindlil
digested lambda phage DNA (Bethesda Research Laboratories,
Paisley, Scotland, UK). DQA1 alleles that could not be fully
resolved by TaqI RFLP methodology were further analyzed by
PCR-RFLP [32]. DQB1 alleles were identified by PCR-RFLP
[33]. In brief, the second exon of each gene was amplified by PCR
and the product digested with a panel of restriction enzymes.
After electrophoresis and visualisation of the restricted products a
typing could be assigned for 8 DQAI alleles and 14 DQB1 alleles.
Statistical methods
The frequency distribution of DQA1 and DQBI alleles in
patient and normal healthy control groups was compared by
Chi-square analysis employing a Fisher's exact two-tailed test.
Where appropriate, P values were corrected for the number of
comparisons made. Since strong linkage disequilibrium exists
between alleles of DQA1 and DQB1 each locus was considered
separately; P values were corrected for 8 comparisons for DQA1
and 14 for DQB1. All quoted P values are corrected P values
unless otherwise stated.
Results
DQA1 alleles
The restriction enzyme TaqI in conjunction with the DQA1
genomic probe revealed five DQA1 related allelic fragments sized
6.8 kb, 6.2 kb, 5.5 kb, 4.6 kb and 2.6 kb [34], corresponding to
fragments 4, 5, 6, 7 and 10 in the Xth HLA Workshop and
identifying DQA1*0103, 0102/04, 0201/0301, 0501 and 0101,
respectively [35]. Subjects typing as 0102/04 or 0201/0301 were
resolved by PCR-RFLP. Concordance between the two DQA1
typing methodologies was confirmed by testing 86 subjects using
both techniques; this revealed only four discrepancies.
The frequency of positivity of the DQA1*0102 allele was
different between Finnish subjects with IgAN and healthy controls
(P = 0.011; Table 1). In the British and Italian groups the DQA1
RFLP frequency distribution was similar between IgAN patients
and healthy controls. The frequency distribution of DQA1 alleles
differed significantly between the three control populations (P <
0.009 uncorrected). The DQA1 probe also identifies a biallelic TaqI
DQA2 RFLP with fragments sized 2.1 kb and 1.9 kb [34]. Within
each of the three population groups the allelic and genotypic
frequency distribution of these alleles was similar for patient and
healthy control groups (Table 2), but differences existed between the
healthy control populations (P < 0.03 uncorrected).
DQB1 alleles
In British Caucasoid patients a decreased frequency of
DQBI°0201 was found (P = 0.008). No differences on DQB1*
allele positivity was found between patients with IgAN and
control subjects in the Italian or Finnish populations (Table 1).
The frequency distribution of DQB1 alleles differed significantly
between the three control populations (P < 0.0001 uncorrected).
Comparison with clinical features
Macroscopic hematuria. The frequency of patients presenting
with macroscopic hematuria in the British, Finnish and Italian
patients were 19%, 13% and 54%, respectively (2 x 3 x2 = 53;
P < 0.001). In each ethnic group no differences in DQA1 or
DQB1 allele frequencies were found between patients presenta-
tion with or without macroscopic hematuria.
Renal impairment. The frequency of patients presenting with
renal impairment in the British, Finnish and Italian patients were
34%, 12% and 23%, respectively (2 x 3 x2 = 10.7; P = 0.005). In
each ethnic group no differences in DQ1 or DQB1 allele frequencies
were found between patients with or without renal impairment.
Discussion
In this study we failed to demonstrate a consistent association
between the HLA-DQ region and IgAN in the three European
Caucasoid populations examined using a more discriminatory
methodology than we or Li and co-investigators previously ap-
plied to British patients alone [22, 23]. We were unable to confirm
our previous finding of an association of IgAN with DQB1*0302,
0303 or 0402 in British patients. This may in part be because in
this study we have used a different control group with a different
frequency of DQB1*0302, but one which is closer to that found in
other studies in British Caucasoid subjects [36, 37].
Neither were we able to confirm the previously reported
association of DQB1*0301 with IgAN in British patients [23].
Although there was a trend for an increased frequency of
DQBI°0301 in Italian and Finnish patients, when corrected for
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Table 1. DQA1 and DQB1 allele positivity in IgAN patients and healthy controls from Britain, Italy and Finland
British subjects Italian subjects Finnish subject
IgANIgAN IgAN
Controls patients Controls patients Controls patients
% (111) % (87) % (49) % (58) % (40) % (40)
DQA1*0101 26.1 (29) 29.9 (26) 32.7 (16) 36.2 (21) 42.5 (17) 52.5 (21)
DQA1*0102 27.9 (31) 31.0 (27) 32.7 (16) 27.6 (16) 45 (18) 12.5 (5)"
DQA1*0103 9.9(11) 17.2 (15) 10.2 (5) 6.9 (4) 17.5 (7) 20(8)
DQA1*0201 31.5 (35) 24.1 (21) 36.7 (18) 27.6 (16) 10 (4) 20 (8)
DQA1*0301 32.4 (36) 37.9 (33) 12.2 (6) 12.1 (7) 30 (12) 32.5 (13)
DQA1*0401 5.4 (6) 2.3 (2) 10.2 (5) 1.7 (1) 12.5 (5) 0(0)
DQAI*0501 45.9 (51) 34.5 (30) 49.0 (24) 67.2 (39) 20(8) 25 (10)
DQA1*0601 0.9 (1) 0(0) 0(0) 0(0) 0(0) 0(0)
DQB1*0501 22.5 (25) 26.4 (23) 24.5 (12) 22.4 (13) 40(16) 52.5 (21)
DQB1*0502 1.8 (2) 1.1 (1) 14.3 (7) 8.6 (5) 2.5 (1) 0(0)
DQB1*0503 5.4 (6) 3.4 (3) 8.2 (4) 13.8 (8) 2.5 (1) 0(0)
DQB1*0504 0.9(1) 0(0) 0(0) 0(0) 0(0) 0(0)
DQBI*0601 0(0) 1.1(1) 2.0(1) 0(0) 0(0) 0(0)
DQB1*0602 18.9 (21) 21.8 (19) 4.1 (2) 10.3 (6) 37.5 (15) 10(4)
DQB1*0603 9.9 (11) 16.1 (14) 8.2 (4) 6.9 (4) 17.5 (7) 20 (8)
DQBI*0604/5 7.2 (8) 9.2 (8) 16.3 (8) 6.9 (4) 12.5 (5) 5 (2)
DQB1*0201 50.5 (56) 26.4 (23)C 38.8 (19) 39.7 (23) 25 (10) 30 (12)
DQB1*0301 36.0 (40) 41.4 (36) 38.8 (19) 62.1 (36) 5 (2) 22.5 (9)
DQB1*0302 9.9(11) 20.7 (18) 10.2 (5) 5.2 (3) 25 (10) 25 (10)
DQB1*0303 15.3 (17) 10.3 (9) 8.2 (4) 1.7 (1) 5 (2) 5 (2)
DQB1*0401 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
DQB1*0402 4.5 (5) 2.3 (2) 10.2 (5) 3.4 (2) 12.5 (5) 0 (0)
" PCR-RFLP is unable to differentiate between DQB1*0602 and 0603, however, knowing the DQA1 typing the distinction can be made since
DQA1*0102 is strongly associated with DQB1*0602 and rarely found with DQB1*0603, and DQA1*0103 is strongly associated with DQB1*0603 and
never found with DQB1*060240
"P = 0.011
= 0.008
Table 2. DQA2 genotype frequencies in IgAN patients and healthy controls from Britain, Italy and Finland
British Subjects Italians Subjects Finnish Subjects
IgANIgAN IgAN
Controls Patients Controls Patients Controls Patients
DQA2
Genotype
(N = 103) (N = 150) (N = 63) (N = 71) (N = 41) (N = 48)
% % %
2.1, 2.1 16 16 8 4 24 19
2.1, 1.9 48 47 43 38 56 46
1.9, 1.9 36 37 49 58 20 35
the number of comparisons made these associations were no
longer significant. Since there is strong linkage disequilibrium
between DQB1*0201 and DR3, in our current study the negative
association with DQB1 *0201 in British patients is consistent with
reports in the French population of a decreased frequency of DR3
in IgAN patients [16].
Similarly, the decreased frequency of DQA1 *0102 in Finnish
patients was likely to be due to a decrease in the Class II haplotype
DR2, DQA1*0102, DQB1*0602. The frequency of DQB1*0602 was
decreased in Finnish patients with IgAN (P = 0.0044 uncorrected);
however, this was no longer significant when corrected for the
number of comparisons made (P = 0.06). In support of this
observation a negative disease association with DR2 has been found
in African Americans and Caucasian Americans [21].
Overall these results would appear to indicate there is no single
DQ allele which predisposes to IgAN in these populations. There
are several possible explanations for these results. Firstly, different
disease susceptibility genes may operate in different populations
and may account for the variation in prevalence in different
geographical locations. The allelic frequency of the DQA1/DQB1
loci differed between the healthy control populations and empha-
sizes the need for matched patients and healthy controls from the
same ethnic background in these studies. Similar differences
within European populations have been previously noted using
serological typing [38]. Nevertheless, if a locus were of primary
importance then its involvement would be detectable in all
populations. Secondly, IgAN is a heterogeneous disease and it has
been suggested that it is two disease sub-entities [39], which may
be determined by different susceptibility genes. Thus, variations in
the clinical composition of the study groups drawn from the three
populations due to differences in local biopsy selection policies
might have influenced our results. Indeed, the proportion of
patients presenting with macroscopic haematuria and renal im-
pairment varied between the three study populations. Therefore,
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heterogeneity between populations and even within populations
may account for some of the controversy surrounding MHC
associations and IgAN.
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